Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/110253

In Collections

This item can be found in the following collections:

Fidder, H.H.; Hommes, D.W. (2010)

Anti-TNF and Crohn's Disease: When Should we Start?

Article / Letter to editor
The natural course of Crohn's disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohn's disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-alpha therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNF's and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphoma's and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up...Show moreThe natural course of Crohn's disease is characterized by the progression from primarily inflammatory disease to a complicated stricturing or penetrating disease. These irreversible complications lead to repeated surgery and considerable disability. Therefore it may be argued that a window of opportunity for intensive treatment exists early in the disease course. Healing of the mucosa has been shown to be a strong predictor of improved outcome of Crohn's disease on the long-term, in terms of disease control, hospitalizations, and surgery. Anti-tumor necrosis factor (TNF)-alpha therapy has shown to be a strong inducer of mucosal healing and it may be argued that early treatment with anti-TNF's and/or immunomodulators may be the preferable approach in selected patients. The main concern with such strategies is safety, especially the risk of lymphoma's and infections. This paper aims to review the existing data regarding the benefits and disadvantages of inverting the classic step up therapeutic paradigm.Show less
Crohn's disease top-down step-up tumor necrosis factor-alpha immunomodulators mucosal healing course of disease immunosuppression inflammatory-bowel-disease antitumor necrosis factor scheduled maintenance treatment single-center cohort randomized-trial monoclonal-antibody certolizumab pegol vienna classification rheumatoid-arthritis natural-history
All authors
Fidder, H.H.; Hommes, D.W.
Date
2010-02-28
Journal
Current Drug Targets
Volume
11
Issue
2
Pages
143 - 147
DOI
doi:10.2174/138945010790309993